Abstract
In January 2013, this column discussed the preliminary fi ndings of the Trial to Assess Chelation Therapy (TACT) based on information presented at the annual meeting of the American Heart Association (AHA). The study has now been published, and the debate regarding its fi ndings shows no signs of stopping.1,2 TACT’s objective was to determine if an ethylene diamine tetra-acetic acid (EDTA) chelation regimen of 40 infusions decreased the risk of cardiovascular events in patients who had a prior myocardial infarction (MI) and who were receiving standard evidencebased post-MI care. The primary endpoint was a composite of death from any cause, reinfarction, stroke, coronary revascularization, or hospitalization for angina. A secondary endpoint was the composite of cardiovascular
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
